XML 40 R29.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Investments in Other Entities (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract] |
Equity Method Investments | Investments in other entities – equity method consisted of the following (in thousands):
| December 31, 2021 |  |  |  | Allocation of Income (Loss) |  | Funding reclassified to loan receivable |  | Funding |  | Entity Consolidated |  | Distribution |  | September 30, 2022
LaSalle Medical Associates – IPA Line of Business | $ | 3,034 |  |  |  |  | $ | 3,885 |  |  | $ | (2,125) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 4,794 |
Pacific Medical Imaging & Oncology Center, Inc. | 1,719 |  |  |  |  | (20) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,699 |
531 W. College, LLC – related party | 17,230 |  |  |  |  | (420) |  |  | — |  |  | 350 |  |  | — |  |  | — |  |  | 17,160 |
One MSO, LLC – related party | 2,910 |  |  |  |  | 306 |  |  | — |  |  | — |  |  | — |  |  | (400) |  |  | 2,816 |
Tag-6 Medical Investment Group, LLC – related party | 4,830 |  |  |  |  | 153 |  |  | — |  |  | 1,435 |  |  | (6,418) |  |  | — |  |  | — |
CAIPA MSO, LLC | 11,992 |  |  |  |  | 493 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 12,485 |
| $ | 41,715 |  |  |  |  | $ | 4,397 |  |  | $ | (2,125) |  |  | $ | 1,785 |  |  | $ | (6,418) |  |  | $ | (400) |  |  | $ | 38,954 |
LMA’s summarized balance sheets at September 30, 2022 and December 31, 2021, and summarized statements of operations for the nine months ended September 30, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands): Balance Sheets
| September 30, 2022 |  | December 31, 2021
| (unaudited) |  | (unaudited)
Assets |  |  |
Cash and cash equivalents | $ | 17,996 |  |  | $ | 6,619 |
Restricted cash | 699 |  |  | 696 |
Receivables, net | 7,355 |  |  | 2,269 |
Loan receivable | 2,250 |  |  | 2,250 |
Total assets | $ | 28,300 |  |  | $ | 11,834 |
Liabilities and Stockholders’ Deficit |  |  |
Current liabilities | $ | 33,468 |  |  | $ | 32,405 |
Stockholders’ deficit | (5,168) |  |  | (20,571) |
Total liabilities and stockholders’ deficit | $ | 28,300 |  |  | $ | 11,834 |
Statements of Operations
| Nine Months Ended September 30,
| 2022 |  | 2021
| (unaudited) |  | (unaudited)
Revenues | $ | 190,731 |  |  | $ | 144,417 |
Expenses | 180,696 |  |  | 155,786 |
Income (loss) from operations | 10,035 |  |  | (11,369) |
Other loss | (48) |  |  | — |
Net income (loss) | $ | 9,987 |  |  | $ | (11,369) |

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration